期刊
THORAX
卷 67, 期 1, 页码 35-41出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2011-200308
关键词
-
资金
- GlaxoSmithKline [FFA109684]
- Merck Sharpe
- Dohme
- AstraZeneca
- Ception
- GlaxoSmithKline
- MedImmune
- Novartis
- UCB Pharma
- National Institute for Health Research [NF-SI-0510-10249] Funding Source: researchfish
Background Fluticasone furoate (FF) is a novel inhaled corticosteroid with 24 h activity. FF is being developed as a once-daily treatment in combination with the long-acting beta(2) agonist vilanterol trifenatate for asthma and chronic obstructive pulmonary disease. Objectives To determine the optimal dose(s) of FF for treating patients with asthma. Methods An 8-week multicentre, randomised, doubleblind study. 627 patients with persistent moderate-to-severe asthma, symptomatic on medium-dose inhaled corticosteroid therapy, were randomised to placebo, FF 200, 400, 600 or 800 mg (once daily in the evening using a novel dry powder inhaler), or fluticasone propionate 500 mg twice daily (via Diskus (TM)/Accuhaler (TM)). The primary efficacy measure was mean change from baseline in pre-dose evening forced expiratory volume in one second (FEV1). Other endpoints included morning and evening peak expiratory flow, and rescue/symptomfree 24 h periods. Results Each dose was significantly superior to placebo for the primary endpoint (p<0.001) with efficacy at least similar to that reported with fluticasone propionate. There was no dose-response relationship across the FF doses studied. Peak expiratory flow improved in all groups (p<0.001 vs placebo), and there were significant treatment effects on rescue/symptom-free 24 h periods with all active treatments. FF was generally well tolerated. The incidence of oral candidiasis was higher with FF 800 mu g than placebo; pharmacokinetic and 24 h urinary cortisol analyses confirmed a higher systemic exposure of FF at this highest dose level. Conclusions FF doses < 800 mu g have a favourable therapeutic index. The absence of an efficacy dose response suggests that 200 mu g is an appropriate dose in patients with moderate persistent asthma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据